Compare Stocks: ORMP, SLN, PHAR, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.59 -3.1%	$13.99	$1.54 ▼ $18.33	$864.42M	0.09	1.36 million shs	5.53 million shs
ORMP Oramed Pharmaceuticals	$4.93 -2.8%	$4.45	$2.09 ▼ $5.47	$210.90M	1.19	227,295 shs	187,973 shs
PHAR Pharming Group	$11.46 +2.3%	$12.36	$9.62 ▼ $21.34	$792.72M	0.01	24,388 shs	5,350 shs
SLN Silence Therapeutics	$14.79	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.93 million shs	572,405 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
ORMP Oramed Pharmaceuticals	-2.76%	-3.33%	+10.54%	+32.88%	+124.09%
PHAR Pharming Group	+2.32%	-2.72%	+11.70%	-9.16%	-20.19%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.59 -3.1%	$13.99	$1.54 ▼ $18.33	$864.42M	0.09	1.36 million shs	5.53 million shs
ORMP Oramed Pharmaceuticals	$4.93 -2.8%	$4.45	$2.09 ▼ $5.47	$210.90M	1.19	227,295 shs	187,973 shs
PHAR Pharming Group	$11.46 +2.3%	$12.36	$9.62 ▼ $21.34	$792.72M	0.01	24,388 shs	5,350 shs
SLN Silence Therapeutics	$14.79	$11.97	$4.19 ▼ $17.58	$890.50M	1.45	1.93 million shs	572,405 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
ORMP Oramed Pharmaceuticals	-2.76%	-3.33%	+10.54%	+32.88%	+124.09%
PHAR Pharming Group	+2.32%	-2.72%	+11.70%	-9.16%	-20.19%
SLN Silence Therapeutics	0.00%	+9.96%	+32.41%	+139.71%	+195.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$25.62	75.57% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
PHAR Pharming Group	2.20	Hold	$38.67	237.41% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	261.73% Upside

Current Analyst Ratings Breakdown

Latest ORMP, SLN, PHAR, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/7/2026	CLYM Climb Bio	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $25.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$23.00
8/3/2026	CLYM Climb Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Moderate Buy	$23.00
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
ORMP Oramed Pharmaceuticals	$2M	102.54	$0.09 per share	55.88	$7.63 per share	0.65
PHAR Pharming Group	$376.13M	2.16	$0.21 per share	55.85	$3.82 per share	3.00
SLN Silence Therapeutics	$560K	1,590.19	N/A	N/A	$0.64 per share	23.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.20	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	95.50	38.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-106.94%	-47.99%	11/5/2026 (Estimated)

Latest ORMP, SLN, PHAR, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	5.07%	N/A	6.07%	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98
PHAR Pharming Group	0.34	3.01	2.31
SLN Silence Therapeutics	N/A	7.42	7.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
ORMP Oramed Pharmaceuticals	12.73%
PHAR Pharming Group	0.03%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
ORMP Oramed Pharmaceuticals	20.77%
PHAR Pharming Group	2.07%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
ORMP Oramed Pharmaceuticals	10	41.60 million	32.96 million	Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
SLN Silence Therapeutics	100	60.21 million	58.40 million	Not Optionable

ORMP, SLN, PHAR, and CLYM Headlines

Recent News About These Companies

Silence Therapeutics to Participate in Three September Investor Conferences

September 2 at 10:16 AM | cityam.com

Silence Therapeutics (NASDAQ:SLN) Stock Price Up 5.8% - Should You Buy?

September 1 at 3:59 PM | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 31, 2026 | marketbeat.com

5AM Venture Management LLC Makes New Investment in Silence Therapeutics PLC Sponsored ADR $SLN

August 26, 2026 | marketbeat.com

Silence Therapeutics: Making Some Recent Noise

August 19, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume - Should You Buy?

August 18, 2026 | marketbeat.com

What is HC Wainwright's Estimate for SLN Q3 Earnings?

August 18, 2026 | marketbeat.com

Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN)

August 17, 2026 | marketbeat.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs

August 14, 2026 | businesswire.com

Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs

August 14, 2026 | cityam.com

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13, 2026 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12, 2026 | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12, 2026 | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11, 2026 | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11, 2026 | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11, 2026 | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11, 2026 | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORMP, SLN, PHAR, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

$14.59 -0.46 (-3.06%)

As of 09/3/2026 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.93 -0.14 (-2.76%)

As of 09/3/2026 04:00 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Pharming Group NASDAQ:PHAR

$11.46 +0.26 (+2.32%)

As of 09/3/2026 04:00 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Silence Therapeutics NASDAQ:SLN

$14.79 0.00 (0.00%)

As of 09/3/2026 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, SLN, PHAR, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, SLN, PHAR, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, SLN, PHAR, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORMP, SLN, PHAR, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

Oramed Pharmaceuticals NASDAQ:ORMP

Pharming Group NASDAQ:PHAR

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, SLN, PHAR, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, SLN, PHAR, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, SLN, PHAR, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ORMP, SLN, PHAR, and CLYM Company Descriptions

Climb Bio NASDAQ:CLYM

Oramed Pharmaceuticals NASDAQ:ORMP

Pharming Group NASDAQ:PHAR

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools